MedCity News April 20, 2021
Vertex Pharmaceuticals is amending its collaboration with CRISPR Therapeutics, paying $900 million now for chance to grab a bigger share of a gene-editing therapy’s profits later—if the treatment is approved. Clinical trials evaluating the CRISPR-based therapy are underway in sickle cell disease and beta thalassemia.
Vertex Pharmaceuticals started its collaboration with CRISPR Therapeutics on gene-editing therapies in a move intended to supplement the Boston company’s franchise of cystic fibrosis drugs. Now the company is amending the pact, grabbing a bigger share of the responsibility, as well as the financial upside, in a bet the bigger company is in the better position to more quickly bring to the market a CRISPR-editing therapy for two rare blood disorders.
The companies announced Tuesday...
Today's Sponsors
Today's Sponsor